Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination...

Area of Science:

• Oncology
• Nephrology
• Rheumatology

Background:

• BRAF and MEK inhibitor combination therapies, including encorafenib plus binimetinib, are first-line treatments for advanced melanoma.
• These therapies present a distinct adverse event profile compared to other combinations like dabrafenib plus trametinib.
• Tubulointerstitial nephritis (TIN) is a recognized, though infrequent, adverse event associated with BRAF/MEK inhibitor combinations.

Observation:

• A patient with rheumatoid arthritis and advanced melanoma was treated with encorafenib plus dabrafenib.
• The patient developed tubulointerstitial nephritis during the course of this combination therapy.

Findings:

• This case highlights the potential for encorafenib plus dabrafenib to induce tubulointerstitial nephritis.
• The occurrence of TIN in a patient with comorbid rheumatoid arthritis adds complexity to the clinical presentation and management.

Implications:

• Clinicians should be vigilant for renal adverse events, particularly tubulointerstitial nephritis, in patients receiving encorafenib plus dabrafenib for advanced melanoma.
• Consideration of comorbidities like rheumatoid arthritis may be important in assessing the risk and presentation of drug-induced nephrotoxicity.
• Further investigation into the mechanisms and risk factors for TIN associated with this specific BRAF/MEK inhibitor combination is warranted.